6ix — Find Your Next Investment

Discover investor relations events, company profiles, and opportunities on 6ix. Connect with public companies and attend live investor events.

Please enable JavaScript to use all features of 6ix.com.

Original text

Rate this translation

Your feedback will be used to help improve Google Translate

Latest Press Releases

Time	Headline
Just now	Duos Technologies to Participate at the 23rd Annual Craig-Hallum Institutional Investor Conference
Just now	ReconAfrica Announces First Quarter Filings
Just now	Matrix Service Company to Participate at Upcoming Stifel Cross-Sector Insight Conference June 2-3, 2026
1m ago	Former Citi Managing Director, Terry O’Neil, Joins Pagaya as Chief Commercial Officer
1m ago	Merck Manuals Answers Common Questions About Hearing Loss and Dementia

About

10.34USD+1.38 +15.40%

Closed • Updated at 13:09 GMT+00:00

Market Cap$917.93M

Volume5.34M

Beta1.37

RSI64.49

Gross Margin97.96%

Health TechnologyBiotechnology

Kura Oncology, Inc. — investor relations, events, news, and company updates on 6ix.

Latest News

Kura Oncology Reports First Quarter 2026 Financial Results

Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress

Kura Oncology to Report First Quarter 2026 Financial Results

Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML

Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib

Community Chat

Ask AI